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Abstract
Background:  The effects of pan-peroxisome proliferator-activated receptor (PPAR) ligand
bezafibrate on N-terminal pro-B type natriuretic peptide (ProBNP) level in patients with coronary
artery disease (CAD) is unknown. The current study aimed to investigate the long-term effects of
bezafibrate on ProBNP level in patients with pre-existing CAD and advanced functional capacity
impairment.
Methods: Metabolic and inflammatory parameters were analyzed from stored frozen serum
samples obtained from 108 patients enrolled in the Bezafibrate Infarction Prevention (BIP) Study.
They presented with New York Heart Association (NYHA) functional class III, comprising 58
patients in the bezafibrate group and 50 in the placebo groups, and completed a 2-year prospective,
double-blind, placebo-controlled follow-up.
Results: During follow-up ProBNP level did not change significantly in the placebo group, whereas
it increased slightly in the bezafibrate group, which was older and with lower baseline ProBNP
values. No significant differences between the groups were found for ProBNP levels after 2 year of
follow-up. Analysis-of-covariance (ANCOVA) -taking into account age and baseline ProBNP level-
showed that bezafibrate was not associated with longitudinal ProBNP changes during the follow-
up period (p = 0.3).
Conclusion: Long-term treatment by bezafibrate was not associated with longitudinal ProBNP
changes in patients with pre-existing CAD and advanced functional capacity impairment.
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Introduction
Bezafibrate is a pan-peroxisome proliferator-activated
receptor (PPAR) ligand with triglyceride-lowering and
high density lipoprotein (HDL)-cholesterol raising effects,
resulting in decreased systemic availability of fatty acid,
diminished fatty acid uptake by muscle, and improve-
ment of insulin sensitizing [1-4]. The Bezafibrate Infarc-
tion Prevention (BIP) Study suggested that bezafibrate
could prevent secondary cardiovascular events in patients
with coronary artery disease (CAD) [5,6]. Although bezaf-
ibrate predominantly acts as a PPARα ligand, its effects
may be in part due to PPARγ activation [1]. PPARγ activa-
tors thiazolidinediones may trigger an aggravation of con-
gestive heart failure [7,9], which counterbalances the
cardiovascular potential benefit of these drugs. This
appears to be mainly due to fluid retention as a conse-
quence of their insulinomimetic action on the kidney
rather than a negative inotropic effect.
Serum N-terminal pro-B type natriuretic peptide
(ProBNP) is a strong and independent prognostic marker
in patients across the spectrum of heart failure stages.
However, the long-term effects of the partial PPARγ ago-
nist bezafibrate on ProBNP level in patients with
advanced functional capacity impairment are unknown.
Therefore, the current study was designed to investigate
the long-term effects of bezafibrate therapy on ProBNP
level in patients with pre-existing CAD and advanced
functional capacity impairment, using the New York
Heart Association (NYHA) class III subgroup of the BIP
Study.
Methods
Subjects
Metabolic and inflammatory parameters were analyzed
from stored frozen serum samples obtained from patients
with advanced impaired functional capacity who com-
pleted a 2-year of prospective, randomized, double-blind,
placebo-controlled Bezafibrate Infarction Prevention
(BIP) Study period. The major inclusion and exclusion cri-
teria for the BIP study, as well as the ethical guidelines,
have been previously reported [5,10]. In brief, inclusion
criteria for men and women comprised: age 45–74 years,
history of myocardial infarction no less than 6 months
and not more than 5 years prior to enrollment into the
study and/or stable CAD confirmed by coronary angiogra-
phy, and/or radio-nuclear studies or standard exercise
tests.
The major exclusion criteria for the BIP study were perma-
nent pacemaker implantation, cerebrovascular disease,
chronic hepatic or renal disease, peripheral vascular dis-
ease, malignant diseases, estrogen replacement therapy,
insulin dependent diabetes mellitus and current use of a
lipid modifying drug. The study was a multicenter pro-
spective trial, performed in 18 university-affiliated hospi-
tals. Patients were allocated to receive either 400 mg of
bezafibrate retard or placebo once a day, in addition to
dietary advice. The follow-up period of the BIP study
lasted until May 1998 (mean 6.2 ± 0.8, range 4.7 to 7.6
years).
Functional status
Functional capacity classes on baseline were evaluated by
certified cardiologists, according to the New York Heart
Association (NYHA) classification [11], following thor-
ough clinical examinations in the framework of university
hospital cardiology departments. Advanced impaired
functional capacity was defined as the a presence of NYHA
functional class III [12]. There were 134 patients with
advanced impaired functional capacity who were
included in the BIP study (73 treated by bezafibrate and
61 by placebo); 128 of them survived after a 2-year fol-
low-up (3 deaths were registered both in bezafibrate and
placebo group). In 20 patients stored frozen serum sam-
ples were missing (12 treated by bezafibrate and 8 by pla-
cebo). Therefore, the final study sample comprised all
patients with NYHA III and full clinicaly and laboratory
data (58 patients on bezafibrate and 50 on placebo).
Coronary artery disease
The diagnosis of CAD was made in patients with docu-
mented myocardial infarction or typical angina pectoris in
whom there was also a positive exercise test, evidence of
myocardial ischemia revealed by radionuclide studies or
at least 60% stenosis of one major coronary artery. Crite-
ria for the diagnosis of MI and anginal syndrome have
been previously reported [10]. Briefly, evidence of MI in
hospitalized patients (0.5 to 5 years prior to beginning of
follow-up) should correspond with class I: a) typical
symptoms, b) increased serum cardiac enzymes, c) elec-
trocardiographic changes: presence of Q/QS and ST-wave
changes according to Minnesota coding, or dynamic
changes of ST-segment (depression/elevation) and T
waves (increasing/decreasing) on comparing 2 consecu-
tive electrocardiograms; class II: b) increased serum car-
diac enzymes, c) electrocardiographic changes: presence
of Q/QS and ST-wave changes according to Minnesota
coding on comparing 2 consecutive electrocardiograms;
class III: a) typical sympoms, c) electrocardiographic
changes: presence of new Q/QS according to Minnesota
coding.
Evidence of anginal syndrome (within 2 years preceding
commencement of follow-up) should correspond with
coronary insufficiency observed at rest or during exertion,
manifested by typical pain and dynamic electrocardio-
graphic changes. These included either spontaneous or
effort induced ST-segment depression of horizontal or
downsloping morphology of ≥1 mm measured at 80 msCardiovascular Diabetology 2009, 8:5 http://www.cardiab.com/content/8/1/5
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from the J point. Reversion to normal or to pre-effort state
should be recorded within 1 hour.
Laboratory methods
Detailed data on laboratory methods were given in previ-
ous reports [10,13]. A central laboratory performed all
biochemical determinations. For the purpose of the
present study, serum samples, which had been taken at
baseline from each study participant and stored at -70°C,
were thawed. ProBNP determinations were performed
within one run, using a Roche Diagnostic ProBNP electro-
chemiluminescent immunoassay kit on a Elecsys 2010
analyser (Roche Diagnostics, Mannheim, Germany)
according to the manufacturer's recommendations. The
intra-assay variability of the ProBNP test in our study was
3.9%.
Determination of additional variables
Criteria for the diagnosis of hypertension have been pre-
viously reported. Smoking habits were determined on the
basis of self-reporting by the patient during an interview
held with a study physician. The homeostatic indexes of
insulin resistance (HOMA-IR) were calculated according
to the homeostasis model of assessment as follows:
HOMA IR = fasting insulin (μU/ml) × fasting glucose 
(mmol/l)/22.5 (or fasting glucose in mg/dl/405)
Statistical analysis
Data were analyzed with SAS software, Version 8.2 (SAS
Institute, Cary, NC, USA). Comparisons of dichotomous
variables and normally distributed continuous variables
were done by the chi-square test and Student's t-test
respectively. Geometric means (GM) were used for triglyc-
erides, insulin, CRP and ProBNP to take into account their
skewed distribution. Non-normally distributed variables
were compared by the nonparametric Kruskal-Wallis test,
and they were log transformed for further analysis. Pear-
son's correlation coefficients for the study population as a
whole were computed for the association between
ProBNP levels and other clinical variables.
Because of their skewed distribution ProBNP was pre-
sented as median and interquartile range, GM and 95%
confidence interval (CI). Absolute changes (μg/ml) of
ProBNP from baseline to 2 year were presented as median
and interquartile range and compared using Kruskal-Wal-
lis test. For the assessment of differences in ProBNP values
after 2 years between bezafibrate and placebo groups an
analysis-of-covariance (ANCOVA) with terms for treat-
ment and baseline values was used based on log-trans-
formed data with adjustment for age.
Results
Baseline data and correlations
Patients in the placebo and bezafibrate groups were well
balanced in terms of clinical and laboratory baseline char-
acteristics and concomitant medications (Table 1, 2). The
Table 1: Baseline characteristics of the study population
Characteristics Bezafibrate
(n = 58)
Placebo
(n = 50)
p value
Age, y 61.1 ± 5.9 59.3 ± 6.2 0.12
Men (%) 53 (91) 46 (92) 0.9
Past myocardial infarction (%) 39 (67) 36 (72) 0.6
Angina (%) 55 (95) 47 (94) 0.9
Hypertension (%) 15 (26) 17 (34) 0.4
Current smokers (%) 7 (12) 6 (12) 0.99
Past smokers (%) 34 (59) 30 (60) 0.9
Body mass index (kg/m2) 27.7 ± 3.8 27.1 ± 3.3 0.4
Systolic blood pressure, mmHg 135 ± 18 133 ± 22 0.5
Diastolic blood pressure, mmHg 81.1 ± 8.1 80.0 ± 10.2 0.4
Glucose, mg/dl 103 ± 19 101 ± 19 0.7
Total cholesterol, mg/dl 211 ± 17 215 ± 18 0.3
HDL-cholesterol, mg/dl 35.4 ± 5.8 35.3 ± 5.1 0.9
LDL-cholesterol, mg/dl 149 ± 15 152 ± 17 0.4
Fibrinogen, mg/dl 348 ± 66 357 ± 70 0.5
Triglycerides, mg/dl 127 (116–140) 135 (124–147) 0.4
CRP (mg/dl) 4.23 (3.40–5.26) 4.66 (3.49–6.23) 0.6
Insulin, μU/ml 4.14 (3.26–5.25) 3.57 (2.70–4.73) 0.4
HOMA-IR 1.02 (0.79–1.31) 0.88 (0.65–1.18) 0.5
ProBNP, pg/ml 154 (118–202) 219 (168–284) 0.07
HDL indicates high density lipoprotein; LDL, low density lipoproteins; CRP, C reactive protein; HOMA-IR, homeostatic index of insulin resistance; 
proBNP, N-terminal pro-B type natriuretic peptide. Data are mean ± SD, geometric mean (95% confidence interval) or number (%) of patientsCardiovascular Diabetology 2009, 8:5 http://www.cardiab.com/content/8/1/5
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study groups were similar regarding gender and the prev-
alence of the most relevant cardiovascular diseases and
risk factors (MI in the past, hypertension, heart failure,
peripheral vascular disease, anginal syndrome, chronic
obstructive pulmonary disease). Patients in the bezafi-
brate group were somewhat older (about 2-years differ-
ence, p = 0.12). No significant differences between the
groups were found for cholesterol and its subfractions,
apolipoproteins, blood pressure, heart rate, fasting glu-
cose, triglycerides, fibrinogen, C-reactive protein (CRP),
creatinine, fasting insulin and HOMA-IR. Serum baseline
concentrations of ProBNP tended to be lower in patients
on bezafibrate (p = 0.07). The natural logarithm (ln) of
ProBNP at baseline was significantly positively correlated
only with age (r = 0.24, p = 0.01). Serum baseline concen-
trations of ProBNP (pg/ml) in accordance with groups of
age are shown in Table 3. Older patients were more fre-
quently on the bezafibrate group (p = 0.04).
Effect of Treatment on Changes in ProBNP
Among patients on placebo, baseline ProBNP level was
somewhat higher than in patients on bezafibrate, but this
difference did not reach statistical significance. No signif-
icant differences between the groups were found for
ProBNP levels after 2 year follow-up, too (Table 4).
Changes in ProBNP from baseline to 2 years of follow-up
(bezafibrate vs. placebo) are shown in Table 5. During fol-
low-up ProBNP level did not change significantly in the
placebo group, whereas it increased slightly in the bezafi-
brate group, which was older and with lower baseline
ProBNP values. However, ANCOVA, which took into
account age and baseline ProBNP level, showed that bez-
afibrate was not associated with longitudinal ProBNP
changes during follow-up (p = 0.3).
Discussion
In the present study we have investigated the effects of
bezafibrate on ProBNP levels in patients with CAD and
advanced functional capacity impairment (NYHA class
III). The results indicate a crude trend for serum increase
in ProBNP level after 2 years of bezafibrate treatment,
compared to placebo. Furthermore, a statistically signifi-
cant difference between both groups was documented
after 2 years treatment for unadjusted ProBNP values.
However, age was somewhat higher and baseline ProBNP
levels tended to be lower in patients treated by bezafi-
brate. Taking into account that the baseline natural loga-
rithm of ProBNP was significantly positively correlated
with age, we re-assessed intra-group differences by
ANCOVA so that the data were adjusted for age and base-
line ProBNP level. As a result, it was evident that bezafi-
brate treatment was not associated with longitudinal
ProBNP changes during 2 years follow-up.
In the BIP study, bezafibrate treatment was associated
with a nonsignificant risk reduction of secondary coro-
nary events in the entire study population despite a mean
of 21% reduction in triglyceride level during a 6.2 year fol-
low up. However, a subgroup of BIP patients with higher
triglyceride values (≥200 mg/dl) on bezafibrate treatment
exhibited a 43% reduction in recurrent coronary risk com-
pared to the placebo group [5]. In the subgroup of
patients with metabolic syndrome, bezafibrate treatment
was associated with a reduced risk for onset of myocardial
infarction with hazard ratio of 0.71 (95% confidence
interval, 0.54–0.95) [14]. In patients with CAD enrolled
in the BIP study, bezafibrate treatment significantly atten-
uated progression of insulin resistance [13] or new onset
of type 2 diabetes [15], compared to placebo. In addition,
Table 2: Distribution of cardiovascular drugs among the study patients
Drugs Bezafibrate
(n = 58)
Placebo
(n = 50)
p value
Beta blockers (%) 29 (50) 26 (52) 0.8
Nitrates (%) 43 (74) 37 (74) 0.99
Calcium antagonists (%) 37 (64) 32 (64) 0.98
Diuretics (%) 6 (10) 10 (20) 0.2
Antiplatelets (%) 39 (67) 36 (72) 0.6
Angiotensin converting enzyme inhibitors (%) 8 (14) 3 (6) 0.2
Table 3: Baseline ProBNP (pg/ml) in accordance with age
Groups of age Patients treated by bezafibrate (%) ProBNP
I (age≤56, n = 29) 12 (41) 129 (96–172)
II (age 57–62, n = 38) 19 (50) 163 (117–227)
III (age≥63, n = 41) 27 (66) 254 (184–349)
P for trend 0.04 0.005Cardiovascular Diabetology 2009, 8:5 http://www.cardiab.com/content/8/1/5
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an extended 8.2 year follow-up indicated that treatment
with bezafibrate was associated with a significant 17% risk
reduction when patients were censored from the analysis
upon initiation of therapy with non study lipid lowering
drugs [6]. These data support a potential benefit of the
treatment with a co-activator of PPARα and PPARγ like
bezafibrate for patients with CAD. However, in this anal-
ysis when the combined end point of cardiac death or
nonfatal MI was analyzed within the prespecified risk sub-
groups, the benefit of bezafibrate therapy was shown to be
most prominent among patients with elevated triglycer-
ides and increased BMI and significantly attenuated
among patients with heart failure or ischemic symptoms
[6]. Recently, the US Food and Drug Administration
required that a "black box" warning for congestive heart
failure be placed on the labels of PPARγ ligands of thiazo-
lidinedione group – pioglitazone and rosiglitazone [16].
Thiazolidinediones, as a class, are well known to increase
fluid retention through unknown mechanisms, which
appear to be the primary contributor to the increased risk
of congestive heart failure with thiazolidinediones [7-9].
In addition to PPARγ, in mouse models of cardiac hyper-
trophy and heart failure, the activation of PPARα has also
been shown to cause noxious effects on the development
of the ventricular function [17,19]. Thus, theoretically
caution should be ought in the use of bezafibrate in
patients with advanced heart failure.
Across the spectrum of heart failure stages, assessment of
ProBNP levels at a single time point in stable outpatient
settings provides a powerful independent prediction of
mortality and new events. Serial testing provides incre-
mental prognostic information: a decrease in levels at fol-
low-up predicts fewer heart failure hospitalizations or
deaths, and an increase in levels predicts a greater likeli-
hood of these adverse outcomes [19-21]. Contrary to bio-
active BNP, biologic activity is absent in ProBNP and its
measurement provides us stable data. Given that ProBNP
levels decrease in response to the addition of therapies
with proven benefit for heart failure, it may be expected
that targeting a given therapy to decrease ProBNP levels
may reduce adverse clinical outcomes. ProBNP secretion
is nonlinear, and when log-transformed peptide levels are
assessed in stable patients, as done in the current study,
these levels appear constant with a variability less than
10% [22,23]. The clinical interpretation is often con-
founded by factors that influence the plasma levels of
ProBNP. For instance, an inverse relation between body
mass index and ProBNP has been observed in patients
with [24] and without heart failure [25,26]. In the current
study, the natural logarithm of ProBNP at baseline was
positively correlated only with age but not with body
mass index. Similarly, renal dysfunction may also influ-
ence the plasma levels of ProBNP, further complicating
Table 4: Serum levels of ProBNP (pg/ml) -bezafibrate vs 
placebo-
Bezafibrate
(n = 58)
Placebo
(n = 50)
Baseline
Geometric mean (95% CI) 154 (118–202) 219 (168–284)
Median (Interquartile range) 151 (89–335) 215 (101–468)
Mean ± SD 254 ± 295 331 ± 326
P = 0.07 (t-test for ln-transformed values)
P = 0.11 (Kruskal-Wallis test)
2-year follow-up
Geometric mean (95% CI) 206 (157–271) 209 (150–292)
Median (Interquartile range) 230 (100–348) 224 (82–503)
Mean ± SD 374 ± 552 389 ± 442
P = 0.95 (t-test for ln-transformed values)
P = 0.85 (Kruskal-Wallis test)
Table 5: Changes in the levels of ProBNP from baseline to 2 year follow-up -bezafibrate vs placebo-
Bezafibrate
(n = 58)
Placebo
(n = 50)
Absolute change
Mean ± SD 120 ± 524 58 ± 307
Median (Interquartile range) 25 (-14–141) -20 (-102–87)
P = 0.02 (Kruskal-Wallis test, unadjusted)
Percent change
Geometric mean (95% CI) 34.1 (8.0–66.3) -4.3 (-21.8–17.0)
Median (Interquartile range) 21.9 (-9.0–111.8) -15.8 (-33.1–46.6)
P = 0.3 (ANCOVA, adjusted for age and baseline ProBNP levels)
P = 0.01 (Kruskal-Wallis test, unadjusted)Cardiovascular Diabetology 2009, 8:5 http://www.cardiab.com/content/8/1/5
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the interpretation of the levels. However, it is logical to
assume that elevated ProBNP values in patients with com-
bined chronic heart failure and chronic kidney disease
have a higher risk for adverse outcomes [27]. The results
of the current study, which indicates no adverse effects of
active treatment on longitudinal ProBNP changes, did not
support a special restriction for bezafibrate use in patients
even with advanced functional capacity impairment such
as a NYHA class III.
Study limitations
The current study included relatively few subjects to pro-
vide definitive explanations regarding the intergroup dif-
ferences in the observed ProBNP level changes at baseline
and at end of follow-up. The analyses were performed ret-
rospectively using stored frozen serum samples obtained
from patients in a subgroup of BIP Study. In addition, any
other data for cardiac function such as echocardiographic
parameters were not available. Future larger-scale control-
led clinical trials targeting cardiac function evaluations
including ProBNP level as a primary endpoint are
required to establish the safety of bezafibrate treatment in
CAD patients with advanced functional capacity impair-
ment.
Conclusion
Long-term bezafibrate treatment was not associated with
longitudinal ProBNP changes in pre-existing CAD
patients with advanced functional capacity impairment.
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